We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Impact of primary tumor-specific growth rate on treatment failure for nonoropharyngeal head and neck cancers.
- Authors
Roldan, Claudia S.; Chen, Jie Jane; Fareed, M. Mohsin; Hameed, M. Yahya; Churilla, Thomas M.; Lango, Miriam N.; Galloway, Thomas J.
- Abstract
<bold>Objectives: </bold>To investigate the prognostic impact of primary tumor-specific growth rate (TSGR) on treatment outcomes after definitive radiation therapy (RT) for nonoropharyngeal squamous cell carcinoma (non-OPSCC).<bold>Methods: </bold>The diagnostic tumor and nodal volumes of 39 non-OPSCC patients were contoured and compared to corresponding RT planning scan volumes to determine TSGR. Overall survival (OS), disease-free survival (DFS), and local recurrence-free survival were evaluated according to the Kaplan-Meier method; and hazard ratios (HR) were estimated using Cox regression. Based on the 75th percentile TSGR of 2.18%, we stratified patients into a high TSGR group (≥ 2.18% per day) and low TSGR group (< 2.18% per day).<bold>Results: </bold>The median follow-up was 22 months (range: 1-86 months) and median time between diagnostic and simulation computed tomography scans was 22 days (range: 7-170 days). Median RT dose was 70 Gy (range: 60-79.2 Gy). Based on the 75th percentile TSGR, OS at median follow-up was 50.0% for the high TSGR group compared to 92.5% for the low TSGR group (HR [95% confidence interval (CI)] = 2.12[1.16-11.42], P = 0.018). There was a trend toward worse DFS at median follow-up for the high versus low TSGR groups, at 55.6% and 82.3%, respectively (HR [95% CI] = 2.29[0.82-6.38], P = 0.103).<bold>Conclusion: </bold>Our study contributes to growing literature on TSGR as a temporal biomarker in patients with non-OPSCC. Patients with high TSGR ≥2.18% per day have significantly worse OS compared to those with TSGR below this threshold. Efforts to address treatment initiation delays may benefit patients with particularly aggressive and rapidly growing tumors.<bold>Level Of Evidence: </bold>4 Laryngoscope, 130:2378-2384, 2020.
- Subjects
HEAD &; neck cancer; SQUAMOUS cell carcinoma; BIOMARKERS; PROGRESSION-free survival; HEAD tumors; DISEASE progression; MAGNETIC resonance imaging; PROGNOSIS; RETROSPECTIVE studies; TREATMENT failure; SURVIVAL analysis (Biometry); RADIATION doses; COMPUTED tomography; NECK tumors
- Publication
Laryngoscope, 2020, Vol 130, Issue 10, p2378
- ISSN
0023-852X
- Publication type
journal article
- DOI
10.1002/lary.28393